HG Capital Leads $23 Million Round in Nuokangda Pharma

HG Capital, a Beijing-based private equity firm, led a $23 million investment in Beijing Nuokangda Pharmaceutical Technology, a CRO company focused on innovative medicine, supplements and medical equipment. Nuokangda plans to use the proceeds to prepare for an IPO on a domestic stock exchange in the near future. Beijing-based K2 Venture Capital, the investment unit of Chinese investment banking firm China Renaissance Partners, also participated. More details.... Share this with colleagues: // //